Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
126. |
ECCT/20/07/03 | STAND A Phase III multicenter, randomized, double blind study to assess efficacy and safety of two doses of crizanlizumab verses placebo, with or without hydroxyurea/hydroxycarbamide therapy in adolescent and adult sickle cell disease patients with Vaso-Occlusive Crises (STAND) |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. CREATES Strathmore University (Nairobi City county) 2. Getrudes Childrens Hospital (Nairobi City county) 3. International Cancer Institute (Elgeyo/Marakwet county) |
View |
127. |
ECCT/20/05/02 | COPCOV Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) |
Principal Investigator(s) 1. Anthony Oliwa Etyang Site(s) in Kenya 1. KEMRI - Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county) 2. KEMRI-Centre for Global Health Research (CGHR) (Kisumu county) |
View |
128. |
ECCT/20/04/03 | 518 & 525-SHAN6™ Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants. Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age |
Principal Investigator(s) 1. Bernhards Ogutu 2. Godfrey Allan Otieno 3. Videlis Nduba 4. Lucy Chepkurui Koech 5. samuel Gurrion Ouma 6. Janet Oyieko Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 3. KEMRI Kondele Children’s Hospital (Kisumu county) 4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county) 5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county) 6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county) 7. CRDR_Siaya Annex(Back-up site) (Siaya county) |
View |
129. |
ECCT/19/12/02 | VPM1002 Phase III PoI A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI-CRDR Nairobi (Nairobi City county) 2. KEMRI-CRDR Siaya (Siaya county) |
View |
130. |
ECCT/19/10/01 | AMC-099 A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions among HIV-Infected Women Participating in an HPV Test-and-Treat Program (COVENANT) |
Principal Investigator(s) 1. ELKANAH ORANGO OMENGE Site(s) in Kenya MOI UNIVERSITY CLINICAL RESEARCH CENTER |
View |